Register For Our Mailing List

Register to receive our free weekly newsletter including editorials.

Home / 322

Four companies riding the healthcare boom

Healthcare is a sector with plenty of tailwinds. This article identifies four companies that stand to benefit from demographic and economic trends while also providing a social good.

Three major trends to follow

Three major trends are underway that are positive for companies operating in the healthcare sector:

  1. The ageing of the population means more money is being spent more on healthcare.
  2. Rising living standards cause people to preference healthcare spending over other consumer goods.
  3. Technology improvements create additional opportunities.

Along with these trends, healthcare is a sector that aligns well with our core beliefs as an ethical funds management business. Healthcare technologies have made phenomemal advances that enable people to live longer, healthier lives. But that doesn’t mean we will invest in any healthcare company. Alongside our disciplined investment criteria we are also guided by the Australian Ethical Charter. For example, we have strict restrictions when it comes to medical testing using animals and we require biotech companies to conduct their research responsibly.

These ethical considerations and economic tailwinds combine to make healthcare a significant part of our Australian Shares Fund at approximately 15-20%. We try not to pay too much attention to macro factors or the index when we think about stocks, and we invest in smaller sized companies which often have a longer pathway of growth.

The healthcare companies we invest in are involved in a range of activities including pharmacy, insurance, radiology, medical devices and different sorts of pharmaceuticals.

Here are four examples of healthcare stocks we hold in our Australian Shares Fund.

Fisher & Paykel Healthcare

Fisher & Paykel is generally associated with household appliances, but it also has a healthcare division which was spun out in 2001. We’ve been invested in Fisher & Paykel Healthcare for around 10 years and it’s a great example of a company that’s managed to reinvent itself several times.

The big discovery for Fisher & Paykel Healthcare was that humidifying air used for breathing during intensive care (ie, emergency situations) improves patient outcomes. They’ve managed to take that core technology into non-invasive ventilation, sleep apnea and some surgical procedures. Their big growth focus currently is re-shaping the delivery of oxygen therapy with their ‘Nasal High Flow’ solution which is used in the care of infants and children.

These products have delivered handsome rewards to investors who have been attracted to Fisher & Paykel’s high-margin recurring consumable earnings. As the stock has appreciated we’ve adjusted our position size down, but they still appear reasonably valued against some higher rated sector peers.


Healius was formerly known as Primary Health Care. It has been a long-term share market underperformer in which we have recently accumulated a position. Their core diagnostic and medical centre assets are potentially strategically valuable despite their operational struggles, and there has been public speculation about corporate activity in the stock. More importantly, we believe earnings have stabilised following a period of decline and the regulatory environment is benign. The company’s balance sheet has improved following a capital raising and the accounting practices of the company have become more conservative through time. Valuation metrics look appealing in the context of the sector.

Capitol Health

Capitol Health is a diagnostic imaging business. This was more of an opportunistic investment for us because it was a company going through quite a lot of problems when we first invested. Like many companies that make lots of acquisitions, it ran into problems after it grew too quickly and took on too much debt. We participated in the recapitalisation of the business at a share price of 14 cents as part of the company’s plan to take out costs and reduce debt.

That strategy played out well with a few ups and downs along the way. The company’s balance sheet received a major boost with the sale of its NSW assets at an attractive price. Capitol Health remains in our portfolio and trades at a reasonable earnings multiple. It’s also within an industry that may present further opportunities for consolidation down the track.


Finally, Cyclopharm is a smaller emerging healthcare technology player that represents a small position in our portfolio. It’s an early-stage company that actually has revenue and pays a dividend, which is somewhat unique for the sector.

Cyclopharm has a lung-imaging solution for patients who are suspected of having pulmonary embolism but who are unable to have CT scans. The company has developed a gas that’s inhaled in a process called ventilation-perfusion. And they’ve actually commercialised this technology already. It’s distributed in 55 countries and has been written up in guidelines as a highly-efficacious technology in that space.

The real opportunity here is that the major market in the world where this technology has yet to be approved is the US. It’s currently going through a clinical trial in the US which has taken longer than expected. But this trial is once more advancing and we’re quite excited about the opportunity it represents for us as investors and for the patients who stand to benefit.


Mike Murray is an Analyst at Australian Ethical, a sponsor of Cuffelinks. This article is general information and does not consider the circumstances of any investor.

For more articles and papers from Australian Ethical, including Graham Hand's interview with AE's Managing Director, Phil Vernon, please click here.



Most viewed in recent weeks

10 little-known pension traps prove the value of advice

Most people entering retirement do not see a financial adviser, mainly due to cost. It's a major problem because there are small mistakes a retiree can make which are expensive and avoidable if a few tips were known.

Check eligibility for the Commonwealth Seniors Health Card

Eligibility for the Commonwealth Seniors Health Card has no asset test and a relatively high income test. It's worth checking eligibility and the benefits of qualifying to save on the cost of medications.

Hamish Douglass on why the movie hasn’t ended yet

The focus is on Magellan for its investment performance and departure of the CEO, but Douglass says the pandemic, inflation, rising rates and Middle East tensions have not played out. Vindication is always long term.

Start the year right with the 2022 Retiree Checklist

This is our annual checklist of what retirees need to be aware of in 2022. It is a long list of 25 items and not everything will apply to your situation. Run your eye over the benefits and entitlements.

At 98-years-old, Charlie Munger still delivers the one-liners

The Warren Buffett/Charlie Munger partnership is the stuff of legends, but even Charlie admits it is coming to an end ("I'm nearly dead"). He is one of the few people in investing prepared to say what he thinks.

Should I pay off the mortgage or top up my superannuation?

Depending on personal circumstances, it may be time to rethink the bias to paying down housing debt over wealth accumulation in super. Do the sums and ask these four questions to plan for your future.

Latest Updates

Investment strategies

Three ways index investing masks extra risk

There are thousands of different indexes, and they are not all diversified and broadly-based. Watch for concentration risk in sectors and companies, and know the underlying assets in case liquidity is needed.

Investment strategies

Will 2022 be the year for quality companies?

It is easy to feel like an investing genius over the last 10 years, with most asset classes making wonderful gains. But if there's a setback, companies like Reece, ARB, Cochlear, REA Group and CSL will recover best.


2022 outlook: buy a raincoat but don't put it on yet

In the 11th year of a bull market, near the end of the cycle, some type of correction is likely. Underneath is solid, healthy and underpinned by strong earnings growth, but there's less room for mistakes.


Time to give up on gold?

In 2021, the gold price failed to sustain its strong rise since 2018, although it recovered after early losses. But where does gold sit in a world of inflation, rising rates and a competitor like Bitcoin?

Investment strategies

Global leaders reveal surprises of 2021, challenges for 2022

In a sentence or two, global experts across many fields are asked to summarise the biggest surprise of 2021, and enduring challenges into 2022. It's a short and sweet view of the changes we are all facing.


What were the big stockmarket listings in record 2021?

In 2021, sharemarket gains supported record levels of capital raisings and IPOs in Australia. The range of deals listed here shows the maturity of the local market in providing equity capital.


Let 'er rip: how high can debt-to-GDP ratios soar?

Governments and investors have been complacent about the build up of debt, but at some level, a ceiling exists. Are we near yet? Trouble is brewing, especially in the eurozone and emerging countries.



© 2022 Morningstar, Inc. All rights reserved.

The data, research and opinions provided here are for information purposes; are not an offer to buy or sell a security; and are not warranted to be correct, complete or accurate. Morningstar, its affiliates, and third-party content providers are not responsible for any investment decisions, damages or losses resulting from, or related to, the data and analyses or their use. Any general advice or ‘regulated financial advice’ under New Zealand law has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. For more information refer to our Financial Services Guide (AU) and Financial Advice Provider Disclosure Statement (NZ). You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Articles are current as at date of publication.
This website contains information and opinions provided by third parties. Inclusion of this information does not necessarily represent Morningstar’s positions, strategies or opinions and should not be considered an endorsement by Morningstar.

Website Development by Master Publisher.